Back to Investors
Lightrock

Lightrock

Venture Capital

Lightrock is a global private equity platform backing purpose-driven entrepreneurs tackling global challenges. The firm invests in scalable and technology-driven business models focused on people, planet, and productivity themes across multiple regions.

Portfolio

2

companies


Portfolio companies

CS

CMR Surgical

CMR Surgical manufactures the Versius system for robotic minimal access surgery.

Selina Finance

Selina Finance

Selina Finance offers home equity lines of credit to unlock property wealth for UK homeowners.


Team

AP

Ash Puri

Growth Investor

UH

Umur Hursever

Partner


Recent investments

£133M

The upsized funding round was led by existing backers including Ally Bridge Group and Lightrock.

"Versius is very well suited to our needs as a world-leading thoracic surgery department. We have successfully helped patients get the benefit of robotic assisted surgery and we look forward to developing our robotics programme working with CMR and other centres around the world as the adoption of Versius continues."
— Adam Peryt
Series B
£26.0M

Lightrock led the equity portion of the round alongside debt financing from Goldman Sachs and GGC to fund expansion.

"Historically, homeowners across the UK have been underserved when it comes to accessing wealth created from their largest asset – their home. Selina’s disruptive lending model allows consumers to unlock previously inaccessible capital, whilst having the flexibility to utilise the lending facility and return as per convenience. The team at Selina have achieved impressive growth with over $100m in loans issued since founding in 2019. Lightrock is delighted to be backing such an innovative team and looks forward to supporting Selina as it disrupts traditionally inflexible lenders."
— Ash Puri, Growth Investor
Series D+
£425M

The funding round was led by SoftBank Vision Fund 2 and co-led by Ally Bridge Group to support international expansion and technological development.

"This latest financing equips CMR with significant funds to accelerate our mission of bringing Versius to hospitals worldwide, whilst providing full flexibility to achieve our goals. This major injection of capital that now values us at $3billion not only reflects the level of interest we have seen in our product, but also the scale of the business, and will enable significant technology developments and global expansion. As the lead investor, SoftBank has a wealth of experience supporting disruptive business models and innovative technologies, and we look forward to leveraging their expertise and extensive ecosystem. I would also like to thank our existing investors for their long-term support."
— Per Vegard Nerseth, Chief Executive Officer